0000000000089971

AUTHOR

Hugo Ten Cate

showing 22 related works from this author

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct

Anticoagulation in Cancer Patients with Atrial Fibrillation and Grade 3-4 Thrombocytopenia

2021

Abstract Introduction: Atrial fibrillation (AF) is not uncommon in cancer patients with grade 3-4 thrombocytopenia (platelets <50x10 9/L). The risk of bleeding appears to outweigh the risk of thrombosis in acute leukemia patients. There are no published data regarding management of anticoagulation (AC) and rates of bleeding and thrombosis in other cancer types. Aim: To assess AC management and incidence of bleeding and thrombosis in thrombocytopenic cancer patients with AF. Methods: Single-center retrospective cohort study. The study included adults with active cancer, grade 3-4 thrombocytopenia (platelets <50x10 9/L) and AF with CHA 2DS 2-VASc ≥1, irrespective of AC status pr…

medicine.medical_specialtybusiness.industryInternal medicineImmunologymedicineCardiologyCancerAtrial fibrillationCell BiologyHematologymedicine.diseasebusinessBiochemistryBlood
researchProduct

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Mean Platelet Volume and Arterial Stiffness - Clinical Relationship and Common Genetic Variability

2017

AbstractVessel wall stiffening is an important clinical parameter, but it is unknown whether platelets, key elements in the pathogenesis of arterial thrombosis, are associated with arterial stiffness. The present studies sought to determine whether mean platelet volume (MPV), a potential marker of platelet activation, is linked to vascular elasticity as assessed by the augmentation index (AIx), in 15,010 individuals from the population-based Gutenberg Health Study. Multivariable analysis showed that MPV in both males (β 0.776; 95thCI [0.250;1.16]; p = 0.0024) and females (β 0.881[0.328;1.43]; p = 0.0018) is strongly associated with AIx. Individuals with MPV and AIx above the sex-specific me…

Male0301 basic medicinemedicine.medical_specialtyPopulationKaplan-Meier Estimate030204 cardiovascular system & hematologyPolymorphism Single NucleotideArticle03 medical and health sciencesSex FactorsVascular Stiffness0302 clinical medicineGUTENBERG HEALTHDEFICIENTINFLAMMATIONRisk FactorsInternal medicinemedicineHumansPlateletPlatelet activationMean platelet volumeeducationMETAANALYSISeducation.field_of_studyMultidisciplinaryHYPERTENSIONbusiness.industryProportional hazards modelHazard ratioGenetic VariationCROSS-SECTIONAL RELATIONSmedicine.diseaseThrombosisElasticityREACTIVITY030104 developmental biologyISCHEMIC-STROKEATHEROSCLEROSISCardiovascular DiseasesArterial stiffnessCardiologyFemalebusinessMean Platelet VolumeVASCULAR FUNCTIONBiomarkers
researchProduct

Predictive Value for Increased Factor XIa and Plasma Kallikrein Activity in Acute Venous Thromboembolism

2021

Abstract Venous thromboembolism (VTE) is associated with increased coagulation activity, which in part can be attributed to the contact pathway of coagulation. Evidence from pre-clinical and epidemiological studies suggests that deficiency in factors of contact activation (e.g. coagulation factors (F) XI and FXII) protects against VTE. However, limited information exists regarding the activation of the contact system in the setting of acute VTE. In the current study, patients with confirmed VTE events (n=321) from the VTEval study and controls (n=300) from the population-based PREVENT-it pilot study were included. Plasma samples were collected from patients after confirmed VTE events or con…

medicine.medical_specialtybusiness.industryImmunologyFactor XIaCell BiologyHematologyBiochemistryPredictive valuePlasma kallikrein activityInternal medicinemedicineCardiologycardiovascular diseasesbusinessVenous thromboembolismBlood
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct

Thrombin generation in cardiovascular disease and mortality – results from the Gutenberg Health Study

2020

Thrombin generation may be a potential tool to improve risk stratification for cardiovascular diseases. The aim of this study was to explore the relation between thrombin generation and cardiovascular risk factors, cardiovascular diseases, and total mortality. For this study, 5,000 subjects from the population-based Gutenberg Health Study were analyzed in a highly standardized setting. Thrombin generation was assessed by the Calibrated Automated Thrombogram method at 1 and 5 pM tissue factor triggers in platelet-poor plasma. Lag time, endogenous thrombin potential, and peak height were derived from the thrombin generation curve. Sex-specific multivariable linear regression analysis adjusted…

medicine.medical_specialtyPercentilePopulationDiseaseDETERMINANTS030204 cardiovascular system & hematologyFACTOR PATHWAY INHIBITORVALIDATIONArticle03 medical and health sciencesTissue factor0302 clinical medicineInternal medicineMedicineeducationPlatelet-poor plasmaeducation.field_of_studyCOAGULATION-FACTORSPLASMAbusiness.industryProportional hazards modelCALIBRATED AUTOMATED THROMBOGRAMHazard ratioORAL-CONTRACEPTIVESHematologymedicine.diseaseObesityTISSUE FACTOROBESITYATRIAL-FIBRILLATIONCardiologybusiness030215 immunologyHaematologica
researchProduct

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observa…

2020

Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated.Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and plateletrelated variables.Findings: VTE cases (N = 159)…

Male0301 basic medicinePlatelet Aggregationlcsh:MedicineDETERMINANTSGastroenterologyMachine LearningPathogenesisACTIVATION0302 clinical medicineRisk FactorsPlateletWhole bloodlcsh:R5-920AspirinOUTCOMESThrombinVenous ThromboembolismGeneral MedicineMiddle AgedThrombosisVenous thrombosis030220 oncology & carcinogenesisAcute DiseaseFemaleDisease Susceptibilitylcsh:Medicine (General)Research Papermedicine.drugBlood Plateletsmedicine.medical_specialtyPlatelet Function TestsGeneral Biochemistry Genetics and Molecular BiologyImmunophenotyping03 medical and health sciencesACUTE PULMONARY-EMBOLISMRISK-FACTORInternal medicinemedicineHumansMean platelet volumeMETAANALYSISAgedPlatelet Countbusiness.industrylcsh:RPlatelet Activationmedicine.diseasePREVENTIONASPIRINTHROMBOSIS030104 developmental biologyPlatelet-rich plasmaVOLUMEbusinessBiomarkersEBioMedicine
researchProduct

The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism

2019

Renal impairment, a source of chronic hypercoagulability[1][1] and inflammation,[2][2] is known to reduce the specificity of the D-dimer test in the diagnosis of venous thromboembolism (VTE).[3][3] This leads to many false positives in such patients and consequently to additional costs, as well as

AdultMalemedicine.medical_specialtyComputed Tomography AngiographyRenal functionSensitivity and SpecificityFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineText miningInternal medicineD-dimermedicineFalse positive paradoxHumansFalse Positive ReactionsProspective StudiesRenal InsufficiencyProspective cohort studyOnline Only ArticlesComputed tomography angiographyAgedProbabilityVenous Thrombosismedicine.diagnostic_testbusiness.industryHematologyVenous ThromboembolismMiddle AgedCardiologyFemalebusinessPulmonary EmbolismVenous thromboembolismAlgorithms030215 immunologyGlomerular Filtration RateHaematologica-the Hematology Journal
researchProduct

Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX

2019

Objectives: FXIa (factor XIa) induces clot formation, and human congenital FXI deficiency protects against venous thromboembolism and stroke. In contrast, the role of FXI in hemostasis is rather small, especially compared with FIX deficiency. Little is known about the cause of the difference in phenotypes associated with FIX deficiency and FXI deficiency. We speculated that activation of FIX via the intrinsic coagulation is not solely dependent on FXI(a; activated FXI) and aimed at identifying an FXI-independent FIX activation pathway. Approach and Results: We observed that ellagic acid and long-chain polyphosphates activated the coagulation system in FXI-deficient plasma, as could be demo…

Malemedicine.medical_specialtyplasma kallikreinPREKALLIKREIN030204 cardiovascular system & hematologyPATHWAYMice03 medical and health sciencesTissue factor0302 clinical medicineThrombinInternal medicinemedicineAnimalsHEMOSTASIScoagulationBLOOD-COAGULATIONBlood CoagulationFactor XIFactor IXfactor IXPURIFICATIONbusiness.industryMOLECULAR-WEIGHT KININOGENThrombinPrekallikreinKallikreinfactor XIfactor XI deficiencyMice Inbred C57BLDEFICIENCYDisease Models AnimalTHROMBOSISEndocrinologyCoagulationTISSUE FACTOR030220 oncology & carcinogenesisHemostasisFemaleREDUCED INCIDENCECardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failure—Results From the MyoVasc Study

2021

Background: Heart failure (HF) is a multifactorial syndrome with pathophysiological complexities still not fully understood. Higher mean platelet volume (MPV), a potential marker of platelet activation, and high concentrations of parathyroid hormone (PTH) have been implicated in the pathogenesis of HF.Aim: This study aims to investigate sex-specifically the association between PTH concentrations and platelet indices in phenotypes of HF.Methods and Results: PTH and platelet indices (MPV and platelet count) were available in 1,896 participants from the MyoVasc study in Mainz, Germany. Multivariable linear regression models, adjusted for age, sex, season, vitamin D status, cardiovascular risk …

heart failure with preserved ejection fractionBIOMARKERmedicine.medical_specialtyPATHOPHYSIOLOGYheart failureParathyroid hormoneCardiovascular Medicine030204 cardiovascular system & hematologyMPVDISEASE03 medical and health sciences0302 clinical medicineInternal medicineMANAGEMENTVitamin D and neurologymedicineDiseases of the circulatory (Cardiovascular) systemparathyroid hormoneheart failure with reduced ejection fractionPlatelet030212 general & internal medicinePlatelet activationMean platelet volumeVITAMIN-DOriginal ResearchRISKEjection fractionbusiness.industryMORTALITYplatelet countmedicine.diseaseDYSFUNCTIONEndocrinologyRC666-701Heart failureCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessFrontiers in Cardiovascular Medicine
researchProduct

Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study.

2016

Mean platelet volume (MPV), a measure of platelet size, is a potential biological marker of platelet function. To date, a comprehensive analysis including known genetic and nongenetic factors that determine MPV is still lacking. MPV has been evaluated in 15 010 individuals from the population-based Gutenberg Health Study. Genetic information was available for 4175 individuals. Our results showed that age (β, 0.0346; 95% confidence interval [CI], 0.0255 to 0.0436), cardiovascular risk factors (CVRFs) such as smoking (β, 0.178; 95% CI, 0.128 to 0.229), hypertension (β, 0.05; 95% CI, 0.00289 to .0981), and high glucose level (β, 0.00179; 95% CI, 0.0006 to 0.00299) were linked with higher MPV i…

0301 basic medicineMalemedicine.medical_specialtyImmunologyPopulationSingle-nucleotide polymorphismDisease030204 cardiovascular system & hematologyBiochemistryGastroenterologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineSex FactorsPolymorphism (computer science)Risk FactorsInternal medicineGenetic variationMedicineHumansGenetic Predisposition to DiseaseGenetic variabilityMean platelet volumeeducationAgedGeneticseducation.field_of_studybusiness.industryAge FactorsThrombosisCell BiologyHematologyMiddle AgedConfidence interval030104 developmental biologyCardiovascular DiseasesFemalebusinessMean Platelet VolumeBlood
researchProduct

Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample

2018

Abstract Background: Tissue factor pathway inhibitor (TFPI), a Kunitz-type serine protease, is a potent anticoagulant protein in the extrinsic coagulation pathway and acts by inhibiting both the FXa and the Tissue Factor-FVIIa complex. In contrast to total and free TFPI antigen levels, the reference values and clinical determinants of total TFPI activity have not yet been studied in detail in the general population. In the present study, we aim to identify the cardiovascular determinants for total TFPI activity and investigate its association with cardiovascular disease (CVD) and total mortality, in a population at large. Methods: For this study, the first 4779 subjects of the population-ba…

business.industryImmunologyCardiovascular risk factorsCoronary arteriosclerosisLarge populationCell BiologyHematologyPharmacologymedicine.diseaseBiochemistryObesityTissue factor pathway inhibitorReference valuesDiabetes mellitusMedicinePlateletbusinessBlood
researchProduct

Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample.

2021

Abstract Objective Tissue factor pathway inhibitor (TFPI) is a potent anticoagulant protein in the extrinsic coagulation pathway. In the present study, we aim to identify the cardiovascular determinants for total TFPI activity and its association with cardiovascular disease (CVD) and total mortality. Methods Total TFPI activity was assessed in a selection of the population-based Gutenberg Health Study (n = 5,000). Statistical analysis was performed to identify the determinants for total TFPI activity as well as the associations with CVD and mortality. Results Multivariable linear regression analysis identified smoking (β 0.095 [0.054–0.136]) as a positive determinant for total TFPI activity…

cardiovascular risk factorsAdultMalemedicine.medical_specialtyLipoproteinsPopulationpopulationCoronary Artery DiseaseTFPICoronary artery diseaseTissue factor pathway inhibitorDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansObesityProspective StudieseducationAgededucation.field_of_studyVENOUS THROMBOEMBOLISMbiologyPLASMAProportional hazards modelbusiness.industrySmokingFactor VWOMENHematologyMiddle Agedmedicine.diseaseObesitymortalitytotal TFPI activityESTROGENEndocrinologyMYOCARDIAL-INFARCTIONFACTOR-VCardiovascular DiseasesHeart Disease Risk Factorsbiology.proteinPopulation studyepidemiologyFemalebusinessThrombosis and haemostasis
researchProduct

Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support

2021

Thrombocytopenia and impaired platelet function are known as intrinsic drawbacks of cardiac surgery and extracorporeal life supports (ECLS). A number of different factors influence platelet count and function including the inflammatory response to a cardiopulmonary bypass (CPB) or to ECLS, hemodilution, hypothermia, mechanical damage and preoperative treatment with platelet-inhibiting agents. Moreover, although underestimated, heparin-induced thrombocytopenia is still a hiccup in the perioperative management of cardiac surgical and, above all, ECLS patients. Moreover, recent investigations have highlighted how platelet disorders also affect patients undergoing biological prosthesis implanta…

medicine.medical_specialtyPlatelet disorderbiological prosthesisRESPIRATORY-FAILUREProsthesis Implantationlcsh:MedicinethrombocytopeniaReview030204 cardiovascular system & hematologyextracorporeal life supportExtracorporeallaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineCardiopulmonary bypassmedicinePlatelet030304 developmental biologyplateletUNFRACTIONATED HEPARIN0303 health sciencesCARDIOPULMONARY BYPASSbusiness.industrylcsh:RMEMBRANE-OXYGENATIONACTIVATED PLATELETSGeneral MedicineHypothermiaENDOTHELIAL-CELLSANTIBODY-FORMATIONCardiac surgeryinflammationCORONARY-ARTERY-BYPASSLife supportAORTIC-VALVE-REPLACEMENTCardiologyHEPARIN-INDUCED THROMBOCYTOPENIAmedicine.symptombusinesscardiac surgeryJournal of Clinical Medicine
researchProduct

Abstract 147: The Role of Thrombin Generation in Cardiovascular Disease and Mortality - Results from the Population-based Gutenberg Health Study

2018

Background: Thrombin formation is one of the key enzymatic processes that direct the activity of the hemostatic system. Thrombin generation (TG), a method addressing the overall potential of a given plasma sample to form thrombin, may be a potential tool to improve risk stratification for cardiovascular diseases (CVD). This study aims to explore the relation between TG and cardiovascular risk factors (CVRFs), CVD, and total mortality. Methods: For this study, N=5000 subjects from the population-based Gutenberg Health Study were analyzed in a highly standardized setting. TG was measured by the Calibrated Automated Thrombogram method at 1 and 5 pM tissue factor (TF) trigger in platelet poor …

Oncologymedicine.medical_specialtybusiness.industryInternal medicineMedicineDiseasePopulation basedCardiology and Cardiovascular MedicinebusinessThrombin generationArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study.

2018

AbstractThe tendency of a plasma sample to generate thrombin, a central enzyme in blood coagulation, might be an important indicator of prothrombotic risk linked to cardiovascular disease (CVD), but the presence of platelets may be a critical determinant. Clinical data, laboratory markers and thrombin generation (TG), investigated in both platelet-rich plasma (PRP) and platelet-free plasma (PFP) at 1 pM TF, were available in 407 individuals from the Gutenberg Health Study. Given the well-known effect of anticoagulants on TG, subjects taking anticoagulants (n = 15) have been excluded resulting in 392 subjects for further analysis. Lag time, endogenous thrombin potential (ETP) and peak height…

0301 basic medicineMaleTime Factorspopulation030204 cardiovascular system & hematologyFibrinogenDISEASEHYPERCOAGULABILITYACTIVATION0302 clinical medicineRisk FactorsGermanyMedicinePlateletProspective StudiesBLOOD-COAGULATIONBlood coagulation testeducation.field_of_studybiologyPlatelet-Rich PlasmaMICROPARTICLESThrombinHematologyclinical epidemiologyMiddle AgedDEFICIENCYC-Reactive ProteinCoagulationCardiovascular Diseasesthrombin generationplateletsFemaleBlood Coagulation TestsMean Platelet Volumemedicine.drugAdultBlood Plateletsmedicine.medical_specialtyPopulationRisk AssessmentMECHANISMS03 medical and health sciencesThrombinINFLAMMATIONPredictive Value of TestsInternal medicineHumansMean platelet volumeeducationBlood CoagulationAgedVENOUS THROMBOEMBOLISMbusiness.industryPlatelet CountC-reactive proteinATHEROTHROMBOSIS030104 developmental biologyEndocrinologybiology.proteinbusinessThrombosis and haemostasis
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Special Issue: "The Latest Clinical Advances in Thrombocytopenia"

2021

Platelets are critical elements in the blood stream, supporting hemostasis as well as performing even more complex tasks within networks of biological (immunity) and pathophysiological processes, such as cancer and ischemia/reperfusion injury [...]

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PATHOPHYSIOLOGYIschemia030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine0502 economics and businessmedicinePlateletIntensive care medicinebusiness.industry05 social sciencesRGeneral Medicinemedicine.diseaseINSIGHTSEditorialn/aHemostasisMedicine050211 marketingbusinessReperfusion injuryBlood streamJournal of Clinical Medicine
researchProduct

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

2018

Background Preclinical data have indicated a link between use of vitamin K antagonists ( VKA ) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population. Methods and Results Clinical and laboratory data, as well as medical–technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5‐hour visit at the study center of the population‐based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an in…

Male0301 basic medicineEpidemiologyPROGRESSION030204 cardiovascular system & hematologyVitamin kCarotid Intima-Media ThicknessTHERAPYGastroenterologyAdrenomedullin0302 clinical medicineRisk Factorscardiovascular diseaseGermanyAtrial FibrillationNatriuretic Peptide BrainMatrix gla proteinOriginal ResearchVenous Thrombosisoral anticoagulationRISKbiologyMiddle AgedStrokevitamin K antagonistsC-Reactive ProteinCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineAtrial Natriuretic Factormedicine.drugAdultmedicine.medical_specialtyPopulation basedMATRIX GLA-PROTEINWARFARIN03 medical and health sciencesVascular StiffnessInternal medicineORAL ANTICOAGULANTmedicineHumansAnkle Brachial IndexVascular structureProtein PrecursorsAgedInflammationVascular diseasebusiness.industryWarfarinAnticoagulantsFibrinogenStroke Volumepharmacogenomic variantsARTERIALmedicine.diseasePreclinical dataPeptide FragmentsCALCIFICATION030104 developmental biologyAsymptomatic DiseasesPhenprocoumonbiology.proteinPulmonary EmbolismbusinessCalcificationJournal of the American Heart Association
researchProduct

Variation of platelet function in clinical phenotypes of acute venous thromboembolism – Results from the GMP‐VTE project

2022

Background The role of platelets in the pathogenesis of venous thromboembolism (VTE) is receiving increasing attention; however, limited information is available on platelet function in the acute phase of the disease. Objective To characterize platelet function according to VTE phenotypes. Patients/Methods In total, 154 subjects (isolated pulmonary embolism [iPE], n = 28; isolated deep vein thrombosis [iDVT], n = 35; DVT+PE, n = 91) were included. In this study platelet function analyzer (PFA)-200, light transmission aggregometry (LTA), thrombin generation (TG) in presence (PRP) and absence (PFP) of platelets and platelet flow cytometry were investigated. LASSO regression was used to select…

medicine.medical_specialtypulmonary embolismPlatelet Function TestsPULMONARY-EMBOLISMplatelet functionDeep veinvenous thromboembolism610 MedizinDETERMINANTSGastroenterologydeep vein thrombosisDISEASEPathogenesischemistry.chemical_compoundPlatelet degranulationRISK-FACTOR610 Medical sciencesInternal medicineHumansMedicinePlateletcardiovascular diseasesPOPULATIONVenous Thrombosisbusiness.industryHematologymedicine.diseaseABSENCEThrombosisPREDICTSPulmonary embolismASPIRINAdenosine diphosphatePhenotypeEpinephrinemedicine.anatomical_structurechemistrythrombin generationVOLUMEbusinessmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct